ClinicalTrials.gg
RecruitingNCT07684976Updated Nov 18, 2026

Safety and Feasibility of Next-Generation Dome Helmet (NGDH) for Focused Ultrasound Neuromodulation in Substance Use Disorder (SUD)

An interventional study of Next Generation Dome Helmet (NGDH) in Substance Use Disorder (SUD), sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 81 studies in Substance-Related Disorders with a site in Canada — 26 open to participants now, 29 under way, none of them phase 3. Substance-Related Disorders · Canada.

Planned enrollment
60th of 71
20 · median 74
Started
2025
with 5 others
No phase
52 of 81
16 open now
Primary completion
2028-07
later than 24 of 28 live
Registered
77th of 81
by date

Among the 81 studies in Substance-Related Disorders with a site in Canada, this one is the 60th largest by planned enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2025, is one of 52 with no phase, reaches primary completion later than 24 of the 28 other live ones, and was the 77th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

26 of the 81 studies in Substance-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Substance-Related Disorders with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, feasibility, and preliminary clinical benefit of focused ultrasound (FUS) neuromodulation using the FUS Next Generation Dome Helmet (NGDH) in adults with treatment-resistant moderate-to-severe substance use disorder (SUD).

The main questions it aims to answer are:

Can FUS neuromodulation be safely delivered to the nucleus accumbens (NAc) and/or anterior insula (aI)? Does FUS neuromodulation result in reduced substance use severity, as measured by Timeline Followback (TLFB), by 4 weeks post-treatment?

Participants will:

Complete baseline clinical assessments, questionnaires, imaging, and safety assessments.

Undergo two MRI-guided FUS neuromodulation sessions approximately 4 weeks apart.

Attend follow-up visits for safety monitoring, symptom assessments, quality-of-life measures, and additional imaging where applicable.

Read the detailed description

A total of 20 participants with treatment-resistant moderate-to-severe substance use disorder (SUD) will be enrolled and treated in this study. Participants will be enrolled from the local practices of the psychiatrists/addiction physicians involved in the study and through outside referrals, including physician referrals or self-referrals. Patient eligibility will be assessed at a screening appointment by the study coordinator and a physician associated with the study. The anticipated enrollment period is approximately two years.

03

Conditions studied

  • Substance Use Disorder (SUD)

Keywords

  • Neuromodulation
  • Focused Ultrasound (FUS)
  • treatment-refractory substance use disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be deemed to have capacity to provide (determined by the investigator)
  2. Age between 18 to 70 (inclusive)
  3. Diagnosis of SUD (cannabis, alcohol, ketamine, stimulant, opioid or nicotine/tobacco use disorder) in the moderate to severe range according to the
  4. Previous ≥2 pharmacotherapy trials for the diagnosed SUD according to guideline-concordant, evidence-based care
  5. On a stable regimen of their psychiatric medications for 30 days before enrolment.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or intending to be pregnant during the study
  2. Known active seizure disorder, significant head injury with an imaging verified lesion
  3. Medical illness that is deemed to be unstable or may confound the effects of the intervention
  4. Not eligible for 3-Tesla MRI (i.e. MRI-incompatible pacemaker)
  5. Unable to reliably attend the required screening, treatment, and follow up appointments.
  6. Severe claustrophobia, identified by the subject to be a limiting factor preventing MRI.
  7. Scores 18 or below on (MoCA)
  8. Weighs 250 lbs or more.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Focused Ultrasound Neuromodulation - NAc First

    Participants will undergo two focused ultrasound (FUS) neuromodulation sessions spaced four weeks apart. Treatments will target the nucleus accumbens and anterior insula. One of the two sessions may include sham exposure or active control sonication.

    Device: Next Generation Dome Helmet (NGDH)

Interventions

  • DeviceNext Generation Dome Helmet (NGDH)

    Focused ultrasound (FUS) neuromodulation delivered using the Next Generation Dome Helmet (NGDH) system under MRI guidance. The device delivers low-intensity pulsed ultrasound to targeted brain regions, including the nucleus accumbens and anterior insula, to modulate neural activity. Participants will undergo two treatment sessions spaced four weeks apart. One session may include sham exposure in which the device is positioned identically but no therapeutic ultrasound energy is delivered.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events

    Safety will be evaluated by assessing the incidence, severity, and relationship of adverse events associated with FUS neuromodulation.

    Time frame: From baseline (prior to first treatment) through 4 weeks after the second treatment, including assessments on the day of each treatment, 1 day, 1 week, and 2 weeks after each treatment, and at 4 weeks after the second treatment.

Secondary outcomes

  1. Change in Number of Drinking Days Using the Timeline Followback (TLFB)

    The Timeline Followback (TLFB) is a validated calendar-based self-report method used to assess daily alcohol consumption over a defined period. Participants will report the number of standard drinks consumed each day over the previous 30 days. The total number of days on which alcohol was consumed will be calculated.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

  2. Change in Average Number of Drinks per Drinking Day Using TLFB

    Participants' daily alcohol consumption over the previous 30 days will be assessed using the TLFB. The average number of standard drinks per drinking day will be calculated.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

  3. Change in Percent Days Abstinent Using TLFB

    Using TLFB data, the percentage of days during the assessment period on which no alcohol was consumed will be calculated.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

  4. Change in Number of Heavy Drinking Days Using TLFB

    Heavy drinking days will be defined as ≥5 drinks per day for men and ≥4 drinks per day for women. The number of such days over the assessment period will be calculated using TLFB data.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

  5. Subjective Ratings of Mood, Anxiety, Energy, and Optimism Using 1-9 Likert Scales

    Participants will complete a brief set of self-reported Likert scales rating their current mood, anxiety, energy level, and optimism for the future. Each item is scored on a 1 to 9 scale, where: 1 = very low/poor 9 = very high/excellent These scales are used to capture rapid, subjective changes in well-being and affective state across the course of treatment.

    Time frame: Baseline, immediately before and after each treatment, 24 hours after each treatment, and 2 and 4 weeks after the second treatment

  6. Change in Depressive Symptoms Using the Hamilton Depression Rating Scale (HAMD-17)

    The HAMD-17 is a clinician-administered scale with 17 items measuring the severity of depressive symptoms. Total scores range from 0 to 52, with higher scores indicating more severe depression.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

  7. Change in anxiety symptoms using the Beck Anxiety Inventory (BAI)

    Anxiety symptoms will be assessed using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire. Each item is scored from 0 to 3, with a total score range of 0 to 63. Higher scores indicate greater anxiety symptom severity. Scores will be compared from baseline to post-treatment follow-up assessments.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

  8. Change in drug use severity using the Drug Use Disorders Identification Test (DUDIT)

    Drug use severity will be assessed using the Drug Use Disorders Identification Test (DUDIT) in participants with drug-related substance use disorder, including stimulant, opioid, and/or ketamine use disorder. The DUDIT is an 11-item instrument used to assess drug-related problems. Items 1-9 are scored from 0 to 4, and items 10-11 are scored as 0, 2, or 4. The total score ranges from 0 to 44, with higher scores indicating greater drug use severity or greater likelihood of drug-related problems. Scores will be compared from baseline to post-treatment follow-up assessments.

    Time frame: Baseline, 3 months after the second treatment, and 6 months after the second treatment

  9. Barratt Impulsiveness Scale (BIS-11)

    The Barratt Impulsiveness Scale (BIS-11) is a widely utilized 30-item self-report instrument for assessing impulsivity. It is designed for the assessment of impulsivity in both research and clinical settings.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

  10. DSM-5 substance use disorders symptom checklist

    11-item checklist based on behaviors over the past 12 months, classified as mild (2-3 symptoms), moderate (4-5), or severe (6+). Key symptoms include failed attempts to cut down, using more than intended, cravings, neglecting obligations, and continued use despite problems.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment.

  11. The Colorado Symptom Index (CSI)

    14-item, self-report questionnaire designed to measure the frequency of psychiatric symptoms (e.g., depression, anxity, psychosis) over the past month.

    Time frame: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2028, 31 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 31 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2025, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Jul 6, 2026
StartActual
Dec 10, 2025was Jul 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Dec 10, 2025 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Jul 2026→Dec 10, 2025 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07684976
Responsible party
Dr. Nir Lipsman (Principal Investigator MD, PHD, FRCSC, FAANS, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Jul 6, 2026
Start date
Dec 10, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Nir Lipsman, MD, PhD, FRCSC
Contact
Nir.Lipsman@sunnybrook.ca
(416)-480-6954
Anusha Baskaran, PhD
Contact
416-480-6100 ext. 61650

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion